“…Loss of heterozygosity of 19p13 was reported in various cancers including thyroid cancer, sex cord stromal tumors, breast cancer, oral carcinoma, prostate cancer, pancreas carcinoma, brain tumors, colorectal carcinoma, gynecological tumors, lung cancers and ovarian carcinoma [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46]. Some of the studies included genetic analysis of STK11/LKB1 and showed mutation in a subset of tumors especially related with Peutz-Jeugher Syndrome such as breast, colorectal, lung, pancreatic, biliary and ovarian cancer [41][42][43][44][45][46][47][48][49]. On the other hand, quite a lot of studies reported mutations and/or loss or various alterations of BRG1 in human cancer lines and primary tumors [50][51][52][53][54][55][56][57][58][59][60][61].…”